Superpower Safety, Regulation & Compliance: An Independent Clinical Assessment

What Is Superpower and How Does It Work?

Superpower positions itself as a "health OS" for high-performers, bundling comprehensive blood panel analysis with prescriptions for GLP-1 receptor agonists, peptides, and hormones through an ongoing subscription model. Members receive a detailed lab draw at a partner CLIA-certified facility, a clinician review, and access to a care team that can prescribe from a menu that includes semaglutide, tirzepatide, and several research peptides.

The Subscription Concierge Model

The concierge format is not unique. Platforms such as Found, Calibrate, and Hims use similar structures: pay a monthly or annual fee, get labs, get a clinician consult, get prescriptions. Superpower's differentiation is mainly in the breadth of its lab panel and the inclusion of peptides that most mainstream platforms decline to prescribe.

Subscription pricing for platforms in this category typically runs $500 to $3,000 per year before medication costs, though exact Superpower pricing is not publicly listed and requires an intake form to access. That opacity makes direct cost comparisons difficult.

Who Oversees the Prescribing?

Licensed physicians and nurse practitioners in the patient's state of residence write all prescriptions. This is a legal requirement, not a brand choice. State medical boards, the DEA, and the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 collectively govern how controlled substances and prescription-only drugs may be dispensed via telehealth. The DEA's interim final rule on telemedicine prescribing has been extended through 2025, meaning that practitioners can still prescribe Schedule III-V controlled substances via telehealth without a prior in-person visit, but only under specific conditions.

GLP-1 Prescribing: Safety and Regulatory Standing

GLP-1 receptor agonists are among the most studied weight-loss and diabetes drugs in modern pharmacology. Semaglutide and tirzepatide have strong efficacy data from large phase-3 trials, and their safety profiles are well-characterized.

What the Phase-3 Data Actually Shows

In the STEP-1 trial (N=1,961), subcutaneous semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [1] Gastrointestinal adverse events were the primary safety signal: nausea in 44.2% of participants, diarrhea in 31.5%, and vomiting in 24.8%, mostly mild to moderate and transient.

The SURMOUNT-1 trial (N=2,539) of tirzepatide 15 mg showed a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo. [2] The GI adverse event profile was similar to semaglutide.

These are large, well-powered, peer-reviewed trials published in the New England Journal of Medicine. Any platform prescribing these agents should be applying the same patient-selection criteria used in those trials: BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity.

The Compounded Semaglutide Problem

From roughly 2022 through early 2025, FDA-listed drug shortages for semaglutide and tirzepatide permitted compounding pharmacies to legally produce compounded versions of both drugs. Superpower, like many platforms in this space, reportedly directed patients to compounding pharmacies during the shortage period.

The FDA resolved the semaglutide shortage and announced its resolution in March 2025, and the tirzepatide shortage was similarly resolved. [3] Per 21 U.S.C. § 503A and § 503B, once a drug is removed from the shortage list, compounding that drug for patient-specific prescriptions becomes legally restricted. The FDA issued guidance making clear that compounding pharmacies must wind down semaglutide production and that patients obtaining compounded versions after the resolution date are receiving a product with an uncertain legal and quality status. [4]

A platform that continues to route patients to compounded GLP-1s after shortage resolution is operating in a legally gray area. Patients should ask their Superpower clinician explicitly whether they are being prescribed FDA-approved branded semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), or a compounded version, and from which pharmacy.

What the FDA Says

The FDA's own language from its March 2025 guidance states: "Patients who are currently taking compounded semaglutide should talk with their health care provider about transitioning to an FDA-approved product." [4] That is a direct instruction, not a suggestion, and it applies equally to patients on any telehealth platform.

Peptide Offerings: The Sharpest Regulatory Edge

Peptides are where Superpower's safety posture becomes most complex. The platform reportedly offers or has offered compounds including BPC-157, TB-500 (thymosin beta-4), sermorelin, ipamorelin, and CJC-1295. Each carries a different regulatory and evidence profile.

FDA Approval Status of Common Peptides

| Peptide | FDA-Approved for Human Use | Published RCT Evidence | |---|---|---| | Sermorelin | Yes (for growth hormone deficiency, withdrawn 2008) | Limited; mainly growth hormone secretion studies | | Ipamorelin | No | Animal models and small human pharmacokinetic studies only | | CJC-1295 | No | Small pharmacokinetic studies, no efficacy RCTs | | BPC-157 | No | Animal models only; no published human clinical trials | | TB-500 (thymosin beta-4) | No | Animal models; one small pilot in cardiac patients |

Sermorelin was FDA-approved but is no longer commercially available as a branded product; it is now only available as a compounded drug, which means it falls under the same 503A/503B compounding rules and cannot be compounded if it is on the FDA's list of drugs that present "demonstrable difficulties." The FDA added several peptides, including BPC-157 and TB-500, to its list of bulk substances that may not be used in compounding in 2024. [5]

The Evidence Gap for Peptides

BPC-157, often marketed for gut healing and tissue repair, has no published phase-1, phase-2, or phase-3 human clinical trials. All published efficacy data comes from rodent models. A 2022 review in Biomolecules examined 16 animal studies and found consistent wound-healing signals in rats and mice. [6] That is interesting preclinical data. It is not evidence of safety or efficacy in humans.

Any platform prescribing BPC-157 to human patients is prescribing a compound with no established human safety profile, no FDA-approved indication, and, as of 2024, a restricted compounding status. Patients should understand that "prescribed by a doctor" does not mean "FDA-approved" or "proven safe in humans."

HealthRX Peptide Risk Stratification Framework

Clinicians reviewing peptide requests from Superpower patients (or any platform's patients) may find this three-tier framework useful:

• Tier 1 (Acceptable with monitoring): FDA-approved compounds available as licensed products. Examples: sermorelin (compounded within 503A rules), tesamorelin (FDA-approved for HIV-associated lipodystrophy).
• Tier 2 (Off-label, limited human data, discuss risk explicitly): Ipamorelin, CJC-1295. Small human pharmacokinetic studies exist; no RCT efficacy data in the target population. Informed consent must document the evidence gap.
• Tier 3 (Decline or refer to clinical trial): BPC-157, TB-500. No human trial data. FDA bulk-substance restriction applies as of 2024. Prescribing these represents an unquantifiable risk that cannot be adequately disclosed because the risk itself is unknown.

Lab Testing: What Superpower Measures and Why It Matters

The lab panel is one area where Superpower's model has genuine clinical merit, provided the results are interpreted by a licensed clinician rather than an algorithm alone.

What a Comprehensive Baseline Panel Should Include

A clinically meaningful hormonal and metabolic panel for an adult seeking GLP-1 or peptide therapy should include, at minimum: CBC with differential, CMP, HbA1c, fasting insulin, fasting glucose, lipid panel, TSH, free T4, testosterone (total and free), SHBG, LH, FSH, estradiol (if relevant), DHEA-S, IGF-1, PSA (for males over 40), and a urinalysis. The American Association of Clinical Endocrinology (AACE) 2023 obesity clinical practice guidelines recommend baseline HbA1c and fasting lipids before initiating any GLP-1 therapy. [7]

Whether Superpower's panel meets or exceeds this standard is not publicly verifiable from its marketing materials. Patients should request the specific CPT codes ordered and compare them to the AACE minimum.

CLIA Certification: The Minimum Bar

Superpower uses partner CLIA-certified laboratories for blood draws. CLIA (Clinical Laboratory Improvement Amendments) certification is the federal minimum standard for labs processing human specimens in the U.S., enforced by CMS. [8] CLIA certification means the lab meets basic accuracy and quality standards. It does not mean the lab is superior to Quest Diagnostics or LabCorp, both of which are also CLIA-certified and used by most competing platforms.

Result Interpretation: Who Reviews and How

The clinically important question is not which lab draws the blood, but who reviews the results and with what protocol. A physician reviewing IGF-1 levels before prescribing a GHRH analog (like CJC-1295) should be applying the Endocrine Society's 2011 growth hormone deficiency guidelines, which require two provocative tests for diagnosis in adults and documented deficiency before treatment. [9] Prescribing a growth hormone secretagogue based on a single IGF-1 value that falls within the lower-normal range would not meet those standards.

Superpower vs. Alternatives: Regulatory Comparison

All U.S. Telehealth platforms prescribing GLP-1s operate under the same federal and state laws. The differences lie in what they prescribe beyond that baseline.

How Competing Platforms Approach Peptides

• Hims / Hers: Prescribes compounded semaglutide (with the same post-shortage legal exposure noted above); does not publicly list peptide offerings.
• Ro: Similar GLP-1 model; declined to offer peptides in its standard catalog as of mid-2024.
• Found: GLP-1 focused; behavioral coaching; no peptide offerings.
• Calibrate: Requires BMI of 30 or higher or 27 or higher with comorbidity; GLP-1 only; no peptides.
• Henry: Testosterone replacement and GLP-1; no peptides publicly listed.

Superpower's willingness to prescribe peptides is its sharpest point of differentiation and also its greatest area of regulatory exposure. A platform that offers fewer interventions is not necessarily worse; it may simply be operating with more conservative risk tolerance for its prescribers.

The Shared Vulnerability: Compounded GLP-1s

Every platform that routed patients to compounding pharmacies during the 2022-2025 shortage period shares the same post-shortage exposure. The FDA has been clear that enforcement discretion for compounded semaglutide ended 90 days after the shortage resolution. Patients on compounded GLP-1s from any platform should have had a transition conversation with their prescriber by June 2025 at the latest.

What Independent Reviews Say (and Their Limitations)

Consumer review platforms such as Trustpilot and Reddit contain hundreds of Superpower testimonials. Positive reviews cluster around the comprehensiveness of the lab panel, the responsiveness of the care team, and weight loss or energy improvements attributed to the prescribed regimen. Critical reviews mention cost, difficulty transitioning away from compounded medications, and variability in clinician quality.

None of this constitutes clinical evidence. The GRADE framework, used by Cochrane and the WHO to rate evidence quality, places individual testimonials at the lowest tier of evidence. [10] Patient satisfaction and clinical safety are related but not equivalent. A patient can feel excellent on a compound that has not been proven safe in humans; they can also feel poorly on a medication with a strong evidence base.

The absence of published outcomes data from Superpower's own patient cohort is a meaningful gap. Platforms with genuine confidence in their clinical model publish outcomes. Calibrate published a 12-month real-world dataset in 2023 showing 15% mean weight loss in 3,400 patients. Superpower has not, to date, published comparable data in a peer-reviewed journal.

Practical Safety Checklist for Prospective Superpower Patients

Before starting any protocol through Superpower or a comparable platform, a patient working with a HealthRX clinician should be able to answer yes to each of these:

1. Is my GLP-1 FDA-approved branded product or compounded? If compounded, ask why and when the transition to branded will occur.
2. Are my baseline labs interpreted by a licensed physician? Algorithmic interpretation without physician sign-off does not meet the standard of care.
3. Has my prescriber documented informed consent for any off-label or unapproved compound? This is a legal and ethical requirement.
4. Do I know which peptides are in Tier 3 (no human data)? BPC-157 and TB-500 should not be prescribed outside a clinical trial setting given current FDA guidance.
5. Is my prescriber licensed in my state? Verify at the FSMB Physician Finder before your first consult.
6. Do I have a follow-up scheduled within 12 weeks of starting any new agent? AACE recommends reassessment at 12 weeks to evaluate GLP-1 tolerability and dose titration. [7]

Clinical Bottom Line on Superpower's Safety Posture

Superpower operates legally under the same framework as every other U.S. Telehealth platform for its GLP-1 and hormone offerings. Its prescribers are licensed; its labs are CLIA-certified; its FDA-approved medication offerings carry the same evidence base as those medications carry anywhere.

The elevated risk lies in three specific areas: compounded GLP-1 persistence after the shortage resolution, peptide offerings that include compounds with no human safety data (BPC-157, TB-500) and a 2024 FDA bulk-substance restriction, and the absence of published outcomes data that would allow independent verification of clinical performance.

Patients who use Superpower for its lab panel and for FDA-approved branded GLP-1 agents, while declining peptides without human trial evidence, are taking on a risk profile comparable to other reputable telehealth platforms. Patients who accept prescriptions for Tier 3 peptides are accepting a risk that cannot currently be quantified from published evidence.

The AACE 2023 obesity guidelines state plainly: "Weight loss pharmacotherapy should be used only as an adjunct to comprehensive lifestyle intervention and only when the benefits are expected to outweigh the risks." [7] That principle applies to every compound on a Superpower prescription pad. Ask your prescriber to show you the evidence that the benefit outweighs the risk. If they cannot, the answer is probably not yet.